FDA approves new treatment for adults with relapsed follicular lymphoma

September 14, 2017 – The U.S. Food and Drug Administration today granted accelerated approval to copanlisib for the treatment of adults with relapsed follicular lymphoma who have received at least two prior treatments known as systemic therapies. “For patients with relapsed follicular lymphoma, the cancer often comes back even after multiple treatments,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of … (leggi tutto)